Sarah frequently advises clients in strategic corporate-commercial and technology transactions in the sectors of life science and TMT, including in-licensing, out-licensing, collaboration, and development agreements in various types of traditional and emerging technology offerings, including software-as-a-service, on-premises software, and technology services and maintenance, and in a broad range of pharmaceutical products and technologies, including biopharmaceutical drugs, immunotherapies, antibody therapeutics, and vaccines.

Before joining MoFo, Sarah was an associate in the Shanghai office of an international law firm. She is fluent in English and Mandarin.

Representative Experience

• A leading healthcare investment firm’s portfolio company in its series of license-in and license-out deals concerning: (i) the development and option agreement and license agreement with a private biotechnological company in the North America for the development of lipid nanoparticles (LNP) formulations for delivery of mRNA and for the commercialization and manufacturing of the protein product and the vaccine product utilizing the LNP technology; and (ii) the licensing-out agreement with a Hong Kong listed company for the development and commercialization of the mRNA technology in Greater China.

• Hangzhou DAC Biotechnology Co., Ltd. on its collaboration and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the development and commercialization of antibody drug conjugate (ADC) products.
• Jiangsu Hengrui Medicine Co., Ltd. in its US$165 million exclusive license agreement with Novaliq GmbH, a German pharmaceutical company focusing on ocular therapeutics, to develop, manufacture and commercialize the innovative, water-free drugs NOV03 (perfluorohexyloctane) and CyclASol® for the treatment of dry eye disease in mainland China, Hong Kong, Macau and Taiwan.
• A FinTech firm in the strategic partnership between a pan-Asia retailer and a Hong Kong bank to construct a new customer loyalty and reward program to replace the current co-branded credit card program on the market.
• An automobile retailer that is a subsidiary of a multi-national dealership operator in its ERP software license and support agreement and the service agreement with a European multi-national software corporation, on the subscription of its core software products and technologies.